View Clinical Trial (Medical Research Study)

A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-19114(Clinical Trial 243226)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Philadelphia
State:  
PA
Zip Code: 19114
Conditions: Optic Neuropathy, Ischemic
Purpose: The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.
Study summary: Sites will identify patients who meet the entry criteria during the conduct of their normal practice. Patients meeting these criteria will be offered participation in the study after reading and completing an informed consent document.
Criteria: Inclusion Criteria: - Male aged ≥45 years; - Experienced abrupt visual change in only 1 eye Exclusion Criteria: - Pain determined by an ophthalmologist to be consistent with an inflammatory/arteritic process or optic neuritis; - History of NAION or optic neuritis. - Participation in other studies within 60 days prior to entry in the study.
Study is available at: Pfizer Investigational Site
Philadelphia, PA 19114
United States

Primary Contact:
Pfizer CT.gov Call Center
Phone: 1-800-718-1021
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.